Joseph G. Jurcic
Department of Medicine
Leukemia Service
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
USA
Name/email consistency: high
- What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia? Jurcic, J.G. Curr. Hematol. Malig. Rep (2011)
- Diagnosis and treatment of acute promyelocytic leukemia. Jurcic, J.G., Soignet, S.L., Maslak, A.P. Curr. Oncol. Rep (2007)
- Immunotherapy for acute myeloid leukemia. Jurcic, J.G. Curr. Oncol. Rep (2005)
- Monitoring PML-RARalpha in acute promyelocytic leukemia. Jurcic, J.G. Curr. Oncol. Rep (2003)
- Targeted alpha particle immunotherapy for myeloid leukemia. Jurcic, J.G., Larson, S.M., Sgouros, G., McDevitt, M.R., Finn, R.D., Divgi, C.R., Ballangrud, A.M., Hamacher, K.A., Ma, D., Humm, J.L., Brechbiel, M.W., Molinet, R., Scheinberg, D.A. Blood (2002)
- Antibody therapy for residual disease in acute myelogenous leukemia. Jurcic, J.G. Crit. Rev. Oncol. Hematol. (2001)
- Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Jurcic, J.G., Nimer, S.D., Scheinberg, D.A., DeBlasio, T., Warrell, R.P., Miller, W.H. Blood (2001)
- Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches. Jurcic, J.G., Cathcart, K., Pinilla-Ibarz, J., Scheinberg, D.A. Curr. Opin. Hematol. (2000)
- Antibody therapy of acute myelogenous leukemia. Jurcic, J.G. Cancer Biother. Radiopharm. (2000)
- Antibody immunotherapy for leukemia. Jurcic, J.G. Curr. Oncol. Rep (2000)